Marcus Shaker1, Tsuzumi Kanaoka2, Lynn Feenan3, Matthew Greenhawt4. 1. Dartmouth-Hitchcock Medical Center, Section of Allergy and Immunology, Hanover, New Hampshire; Dartmouth Geisel School of Medicine, Hanover, New Hampshire. Electronic address: Marcus.S.Shaker@hitchcock.org. 2. Dartmouth Geisel School of Medicine, Hanover, New Hampshire. 3. Dartmouth-Hitchcock Medical Center, Section of Allergy and Immunology, Hanover, New Hampshire. 4. Children's Hospital Colorado, University of Colorado School of Medicine, Section of Allergy and Immunology, Aurora, Colorado.
Abstract
BACKGROUND: Layperson food allergy management plans commonly stipulate that if epinephrine is used to immediately call 911 and seek care in the nearest medical facility for observation. OBJECTIVE: To evaluate the cost-effectiveness of this strategy, vs a watchful waiting approach before activating emergency medical services (EMS). METHODS: We performed a cost-effectiveness analysis using Markov modeling simulated over a 20-year horizon comparing activating EMS immediately after epinephrine use for allergic reactions to peanut vs a "wait and see" approach in which EMS was only activated if symptoms of the reaction did not promptly resolve after treatment. The base-case model assumed a 10-fold increased fatality risk with delayed EMS activation. RESULTS: The fatality risk associated with early EMS use was minimal, with a per-patient fatality rate over a 20-year horizon of 1.2 × 10-6, vs 1.9 × 10-6 for a wait and see approach. The incremental cost per life-year saved was $142,943,447 for early EMS vs wait and see, with the cost per death prevented reaching $1,349,335,651 as the simulation concluded. Cost of early EMS activation rose to $321,625,534 per life-year saved ($3,035,454,848 per death prevented) if a 5-fold increase in fatality risk was assumed, and was $12,997,173 per life-year saved ($122,689,936 per death prevented) if a 100-fold increase in fatality risk was assumed. CONCLUSION: Medical observation of a treated and promptly resolved peanut allergic reaction has minimal benefit and excessive costs. Immediately activating EMS after using epinephrine for a peanut allergic reaction in this context is not cost-effective.
BACKGROUND: Layperson food allergy management plans commonly stipulate that if epinephrine is used to immediately call 911 and seek care in the nearest medical facility for observation. OBJECTIVE: To evaluate the cost-effectiveness of this strategy, vs a watchful waiting approach before activating emergency medical services (EMS). METHODS: We performed a cost-effectiveness analysis using Markov modeling simulated over a 20-year horizon comparing activating EMS immediately after epinephrine use for allergic reactions to peanut vs a "wait and see" approach in which EMS was only activated if symptoms of the reaction did not promptly resolve after treatment. The base-case model assumed a 10-fold increased fatality risk with delayed EMS activation. RESULTS: The fatality risk associated with early EMS use was minimal, with a per-patient fatality rate over a 20-year horizon of 1.2 × 10-6, vs 1.9 × 10-6 for a wait and see approach. The incremental cost per life-year saved was $142,943,447 for early EMS vs wait and see, with the cost per death prevented reaching $1,349,335,651 as the simulation concluded. Cost of early EMS activation rose to $321,625,534 per life-year saved ($3,035,454,848 per death prevented) if a 5-fold increase in fatality risk was assumed, and was $12,997,173 per life-year saved ($122,689,936 per death prevented) if a 100-fold increase in fatality risk was assumed. CONCLUSION: Medical observation of a treated and promptly resolved peanutallergic reaction has minimal benefit and excessive costs. Immediately activating EMS after using epinephrine for a peanutallergic reaction in this context is not cost-effective.
Authors: Marcus S Shaker; John Oppenheimer; Mitchell Grayson; David Stukus; Nicholas Hartog; Elena W Y Hsieh; Nicholas Rider; Cullen M Dutmer; Timothy K Vander Leek; Harold Kim; Edmond S Chan; Doug Mack; Anne K Ellis; David Lang; Jay Lieberman; David Fleischer; David B K Golden; Dana Wallace; Jay Portnoy; Giselle Mosnaim; Matthew Greenhawt Journal: J Allergy Clin Immunol Pract Date: 2020-03-26
Authors: Marcus S Shaker; Giselle Mosnaim; John Oppenheimer; David Stukus; Elissa M Abrams; Matthew Greenhawt Journal: J Allergy Clin Immunol Pract Date: 2020-05-14